ProCE Banner Activity

Cases in CLL: Frontline Therapy Selection and Clinical Trial Considerations for a Patient With Multiple Comorbidities

Clinical Thought
In this commentary, an expert faculty discusses key considerations and shared decision-making in choosing treatment for a patient with CLL.

Released: July 07, 2022

Expiration: July 06, 2023

No longer available for credit.



Lindsey Roeker

Lindsey Roeker, MD

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from

AbbVie Inc.


Eli Lilly

Janssen Biotech

Pharmacyclics an AbbVie Company

TG Therapeutics


CLL Society

ProCE Banner

Faculty Disclosure

Primary Author

Lindsey Roeker, MD

Lindsey Roeker, MD: consultant: AbbVie, Ascentage, AstraZeneca, BeiGene, Janssen, Loxo, Pfizer, Pharmacyclics, TG Therapeutics; research funding (to institution): Aptose, Loxo, Pfizer; minority ownership interest: Abbott.